Biorestorative Therapies, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: BioRestorative Therapies Grants Significant Stock Option to VP of R&D, Boosting Executive's Stake to 15.1%
BioRestorative Therapies, Inc. has granted a substantial stock option to its Vice President of Research and Development, Francisco Silva, increasing his beneficial ownership to approximately 15.1% of the company's common stock.
NASDAQ
BioRestorative Therapies, Inc. has granted its CEO, Lance Alstodt, a ten-year option to purchase 791,885 shares of common stock at an exercise price of $2.46 per share, significantly increasing his beneficial ownership to 15.5%.